Frequently Asked Questions (FAQs)

The 4-month rifapentine-moxifloxacin tuberculosis (TB) treatment regimen consists of high-dose daily rifapentine with moxifloxacin, isoniazid, and pyrazinamide. It has an intensive phase of 8 weeks, followed by a continuation phase of 9 weeks (total 17 weeks for treatment).

Shorter regimens help patients complete treatment faster. Healthcare providers can choose the appropriate TB treatment regimen based on drug-susceptibility results, coexisting medical conditions (e.g., HIV, diabetes), and potential for drug-drug interactions. The State TB Control Offices and TB Centers of Excellence for Training, Education, and Medical Consultation can provide additional assistance and support in treating people with TB disease.

For more information, refer to Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022. MMWR Morb Mortal Wkly Rep, 2022.


Sputum Samples

Drug Susceptibility Testing

Baseline Patient Evaluations

Patient Considerations

Drug Information

Related Links